



NATIONAL LGBTQIA+ HEALTH  
EDUCATION CENTER

A PROGRAM OF THE FENWAY INSTITUTE

# Telehealth and PrEP/HIV Care Outcomes

.....

Dr. Ken Mayer

Dr. Taimur Khan

Friday, June 11<sup>th</sup> 2021

# Our Roots

## Fenway Health

- Independent 501(c)(3) FQHC
- Founded 1971
- Mission: To enhance the wellbeing of the LGBTQIA+ community as well as people in our neighborhoods and beyond through access to the highest quality health care, education, research, and advocacy
- Integrated primary care model, including HIV and transgender health services

## The Fenway Institute

- Research, Education, Policy



# LGBTQIA+ Education and Training

The National LGBTQIA+ Health Education Center offers educational programs, resources, and consultation to health care organizations with the goal of providing affirmative, high quality, cost-effective health care for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and all sexual and gender minority (LGBTQIA+) people.

- Training and Technical Assistance
- Grand Rounds
- Online Learning
  - Webinars, Learning Modules
  - CE, and HEI Credit
- ECHO Programs
- Resources and Publications

[www.lgbtqiahealtheducation.org](http://www.lgbtqiahealtheducation.org)



# National Association of Community Health Centers, Inc. (NACHC)

[www.NACHC.org](http://www.NACHC.org)

**The National Association of Community Health Centers (NACHC) was founded in 1971 to “promote efficient, high quality, comprehensive health care that is accessible, culturally and linguistically competent, community directed, and patient centered for all.” NACHC represents community health centers across the country. Community Health Centers serve as the primary medical home for 27 million people in close to 11,000 underserved communities across America.**



NATIONAL LGBTQIA+ HEALTH  
EDUCATION CENTER

A PROGRAM OF THE FENWAY INSTITUTE



NATIONAL ASSOCIATION OF  
Community Health Centers

# Technical Questions?

- Please call Zoom Technical Support: 1.888.799.9666 ext 2
- You can contact the webinar host using the chat function in Zoom. Click the “Chat” icon, and type your question.
- Alternatively, e-mail us at [education@fenwayhealth.org](mailto:education@fenwayhealth.org) for less urgent questions.

# Sound Issues?

- Ensure your computer speakers are not muted.
- If you cannot hear through your computer speakers: Navigate to the bottom toolbar on your screen, go to the far left, and click the arrow next to the phone icon.
- Choose “I will call in.”
- Dial the phone number and access code.

# When the webinar concludes:

- Close the browser, and an evaluation will automatically open for you to complete.
- We very much appreciate receiving feedback from all participants.
- Completing the evaluation is required to obtain a CME/CEU certificates.

# CME/CEU Information

This activity has been reviewed and is acceptable for up to 1.0 Prescribed credits by the American Academy of Family Physicians. Participants should claim only the credit commensurate with the extent of their participation in this activity.

<b>Physicians</b>	AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit™ toward the AMA Physician's Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.
<b>Nurse Practitioners, Physician Assistants, Nurses, Medical Assistants</b>	AAFP Prescribed credit is accepted by the following organizations. Please contact them directly about how participants should report the credit they earned. <ul style="list-style-type: none"><li>•American Academy of Physician Assistants (AAPA)</li><li>•National Commission on Certification of Physician Assistants (NCCPA)</li><li>•American Nurses Credentialing Center (ANCC)</li><li>•American Association of Nurse Practitioners (AANP)</li><li>•American Academy of Nurse Practitioners Certification Program (AANPCP)</li><li>•American Association of Medical Assistants (AAMA)</li></ul>
<b>Other Health Professionals</b>	Confirm equivalency of credits with relevant licensing body.



# Learning Objectives:

- In this session, participants will:
  1. Learn about current research in telehealth and PrEP/HIV care outcomes, including PrEP @ Home and considerations for the administration and management of PrEP during COVID-19.
  2. Explore the topic of PrEP implementation in a health center setting.
  3. Discover best practices for PrEP systems of care and improving adherence.

## Sexual Health in the SARS-CoV-2 Era

Jack L. Turban, MD, MHS; Alex S. Keuroghlian, MD, MPH; and Kenneth H. Mayer, MD

**M**ore than 200 000 people have died of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection, leading to widespread concern regarding physical morbidity and mortality. The sexual health implications, however, have received little focus. On the basis of existing data, it appears all forms of in-person sexual contact carry risk for viral transmission, because the virus is readily transmitted by aerosols and fomites. This has resulted in broad guidance regarding physical distancing, with substantial implications for sexual well-being. Given the important role of sexuality in most people's lives, health care providers (HCPs) should consider counseling patients on this topic whenever possible. This is an unprecedented and stressful time for HCPs; facilitating brief conversations and referrals to relevant resources (Table) can help patients maintain sexual wellness amid the pandemic.

**CURRENT EVIDENCE SUGGESTS THAT ALL  
IN-PERSON SEXUAL CONTACT CARRIES  
TRANSMISSION RISK**



transmission owing to the virus' stability on common surfaces and propensity to propagate in the oropharynx and respiratory tract.

### PSYCHOLOGICAL EFFECTS OF SEXUAL ABSTINENCE

Sexual expression is a central aspect of human health but is often neglected by HCPs. Messaging around sex being dangerous may have insidious psychological effects at a time when people are especially susceptible to mental health difficulties. Some groups, including sexual and gender minority (SGM) communities, may be particularly vulnerable to sexual stigma, given the historical trauma of other pandemics, such as AIDS. Abstinence recommendations may conjure memories of the widespread stigmatization of SGM people during the AIDS crisis. For the population at large, a recommendation of long-term sexual abstinence is unlikely to be effective, given the well-documented failures of abstinence-based public health interventions and their likelihood to promote shame (8).

# SARS-COV-2 transmission

- SARS-CoV-2 binds and replicates in the upper airway and oropharynx
- Mainly transmitted by droplets (>5 microns), aerosols?, fomites?
- 3 studies did not find virus in semen or cervicovaginal secretions, but 1 found 3/38 semen polymerase chain reaction positive (PCR+) (Li, JAMA Netw Open)
- 1 study found virus in urine (Wang, JAMA)
- 1 study found virus in stool (Chen, Med Virol)
- However, the clinical significance is unclear, since PCR+ does not necessarily indicate that replication competent virus is present



# Sexual health counseling in the COVID-19 era

- Basic principle: sexual expression is central for health
- Any direct contact has the potential to transmit infection
- So, counseling needs to focus on sexual harm reduction, i.e., enabling the patient to understand risks and benefits and to develop strategies to mitigate risks while addressing personal needs.



# Sexual health counseling in the COVID-19 era

- Messages that sex is bad may be perceived as stigmatizing, particularly for sexual and gender minority people
- Provide resources for lowest risk activities
- Abstinence over extended periods for sexually active people may not be realistic



# Sexual practices during the SARS-CoV-2 era and patient resources

**Table.** Sexual Practices During the SARS-CoV-2 Era and Patient Resources

Sexual Approach	Summary
Sexual abstinence	Low risk for infection, though not feasible for many
Masturbation	Low risk for infection Safe masturbation tips (Planned Parenthood): <a href="https://www.plannedparenthood.org/learn/sex-pleasure-and-sexual-dysfunction/masturbation">https://www.plannedparenthood.org/learn/sex-pleasure-and-sexual-dysfunction/masturbation</a>
Sexual activity via digital platforms, such as the phone or video chat	Patients should be counseled on the risk for screenshots of conversations or videos and sexual extortion Minors should be counseled on potential legal consequences if they are in possession of sexual images of other minors Minors should be counseled on the risks for online sexual predation, which has increased since the pandemic began Speaking with children about sexual risk online during COVID-19 (Scientific American): <a href="https://www.scientificamerican.com/article/the-coronavirus-pandemic-puts-children-at-risk-of-online-sexual-exploitation/">https://www.scientificamerican.com/article/the-coronavirus-pandemic-puts-children-at-risk-of-online-sexual-exploitation/</a>
Sex only with those with whom one is self-quarantined	Patient is at risk for infection from sex partner if they have been exposed while outside the home Patient is at risk for infection from an asymptomatic SARS-CoV-2-infected partner
Sex with persons other than those with whom one is self-quarantined	Patient should be counseled on the risk for infection from partners, as well as risk reduction techniques that include minimizing the number of sexual partners, avoiding sex partners with symptoms consistent with SARS-CoV-2, avoiding kissing and sexual behaviors with a risk for fecal-oral transmission or that involve semen or urine, wearing a mask, showering before and after sexual intercourse, and cleaning of the physical space with soap or alcohol wipes COVID-19 and Your Sexual Health (Fenway Health): <a href="https://fenwayhealth.org/wp-content/uploads/C19MC-11_Sex-and-COVID-19-Materials_flyer2.pdf">https://fenwayhealth.org/wp-content/uploads/C19MC-11_Sex-and-COVID-19-Materials_flyer2.pdf</a> Guidance on COVID-19 and sexual health (New York City Department of Health): <a href="https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-sex-guidance.pdf">https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-sex-guidance.pdf</a>
<b>Additional resources</b> Building Health Communities Online – Sex Partner Notification Platform: <a href="https://tellyourcontacts.org/">https://tellyourcontacts.org/</a> What to Know About HIV and COVID-19 (Centers for Disease Control and Prevention) <a href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/hiv.html">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/hiv.html</a> COVID-19 Command Center for STD Programs(National Coalition of STD Directors) <a href="https://www.ncsddc.org/resource/covid-command-center-for-std-programs/">https://www.ncsddc.org/resource/covid-command-center-for-std-programs/</a>	

COVID-19 = coronavirus disease 2019; SARS-CoV-2 = severe acute respiratory syndrome-coronavirus-2; STD = sexually transmitted disease.

# Online intimacy



- Proliferation of videochat vs. meeting in person
- Patients should be counseled on the risk for screenshots of conversations or videos and sexual extortion
- Minors should be counseled on the risks for online sexual predation, which has increased since the pandemic began
- Speaking with children about sexual risk online (Scientific American):

<https://www.scientificamerican.com/article/the-coronavirus-pandemic-puts-children-at-risk-of-online-sexual-exploitation/>

FENWAY  HEALTH



# COVID-19 and Your Sexual Health



NATIONAL LGBTQIA+ HEALTH  
EDUCATION CENTER

A PROGRAM OF THE FENWAY INSTITUTE



NATIONAL ASSOCIATION OF  
Community Health Centers




# Impact of COVID-19 on sexual behavior in men who have sex with men (MSM)

- National on-line survey 2 weeks in April, 2020
- 1,051 respondents in AMIS cohort (Sanchez, AIDS and Behav)
- 51% ↓ sex; 48% stayed the same; 9% ↑.
- 68% found fewer opportunities for sex; 27% thought it was the same, and 4% found more.
- 1/10 reported reported ↑ drug use and 25% ↑ alcohol
- Younger MSM (15-24) were more likely to report more app, alcohol and drug use, and less access to condoms




# Number of patients with an active HIV pre-exposure prophylaxis (PrEP) prescription decreased by 18%.

Number of PrEP refill lapses increased by 191%; PrEP starts decreased by 72%.




Krakower et al. OACLB0104

# Human immunodeficiency virus (HIV), Gonorrhea (GC) and Chlamydia (CT) testing decreased by 85.1%, but GC/CT test positivity increased by 3.5%.



Krakower et al. OACLB0104

# A major shift from in-person visits to telehealth occurred



Krakower et al. OACLB0104

# PrEP refill lapses were associated with age, race, and ethnicity

	Refill lapse (N = 407) n (%)	Active prescription (N = 2611) n (%)	% Lapse	
Age, yrs				
≤ 26	87 (21.3)	395 (15.1)	18.0	p=0.001
27+	320 (78.6)	2216 (84.8)	12.6	
Race				
White	275 (67.2)	1943 (74.4)	12.4	p=0.001
Black/African-American	25 (6.1)	151 (5.8)	14.2	
Asian	26 (6.4)	155 (5.9)	14.4	
AI/AN + Other	33 (8.1)	205 (7.9)	13.9	
Multiracial	25 (6.1)	91 (3.5)	21.6	
Unknown/Not Reported	23 (5.6)	66 (2.5)	25.8	p=0.04
Ethnicity				
Hispanic	68 (16.7)	324 (12.4)	17.3	
Non-Hispanic	301 (74.0)	2060 (78.9)	12.7	
Unknown/Not Reported	38 (9.3)	227 (8.7)	14.3	

Krakower et al. OACLB0104

# PrEP refill lapses were also associated with insurance type

	Refill lapse (N=407) n (%)	Active prescription (N=2611) n (%)	% Lapse	
Gender Identity				
Cisgender Male	376 (91.9)	2416 (92.5)	13.5	$p=0.21$
Cisgender Female	3 (0.7)	18 (0.7)	14.3	
Transgender or Genderqueer	22 (5.4)	102 (3.9)	17.7	
Unknown/Not Reported	6 (1.5)	75 (2.9)	7.4	$p=0.002$
Type of Insurance				
Public	71 (17.4)	294 (11.3)	19.5	
Private	331 (81.4)	2286 (87.6)	12.6	
Uninsured/Other	5 (1.2)	31 (1.2)	13.9	

Krakower et al. OACLB0104

# Providing tailored, appropriate care

Home care system for PrEP could reduce clinician visits from 4/year to 1/year

<https://vimeo.com/138977095>

EMORY UNIVERSITY

**PrEP**  
AT HOME 



**1. Kit mailed**








**2. Urine, throat, rectal specimens**



**3. Blood specimens**



**4. Prepaid mailer, survey**

Participant Test Summary Form				PrEP@ Home	
<b>Participant Information</b>					
Participant Name	Doe	John	E		Optimal
	Last	First	MI		Elevated
					High
Date Specimens Collected	6/13/2016				
Date Specimens Tested	6/17/2016				
<b>Section 1: HIV Testing</b>					
HIV	Oraquick		Interpretation: Non-Reactive HIV test		
<b>Section 2: Symptomatic Screening for Acute HIV</b>					
Fever, Swollen Glands, Sore Throat, Muscle and Joints Aches and Pains,				Interpretation: No Acute HIV symptoms	


**5. Results report to clinician**



**6. Rx, care as needed**

Siegler AJ, Mayer KH, Liu AY, Patel RR, Ahlschlager LM, Kraft CS, et al. Developing and assessing the feasibility of a home-based PrEP monitoring and support program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;Jul 4.

# Pilot results: Usability



**87% indicated they would like to use PrEP@Home in place of their next in-person clinical visit**

**40% would have a greater likelihood of remaining on PrEP if PrEP@Home was available**

**Next step: RCT (NIMH: R01MH114692, PI Siegler and Mayer) to determine retention in care and cost-effectiveness.**

Siegler AJ, Mayer KH, Liu AY, Patel RR, Ahlschlager LM, Kraft CS, et al. Developing and assessing the feasibility of a home-based PrEP monitoring and support program. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018



## Examples of Remote Collection and Monitoring

- Molecular Testing Labs can ship to all US states apart from NY, NJ, and RI
- Nurx ([www.nurx.com](http://www.nurx.com)) provides remote sexual health care

### PrEP Related Assays

- HIV
- Creatinine
- HBV
- HCV
- Syphilis
- TFV-dp
- 3-site Chlamydia
- 3-site Gonorrhea

### Collection Methods

- Dried Blood Spot (DBS)
- Blood Microtainer
- Serum Separator Card
- Wet Urine
- Saliva
- Buccal Swab
- 3 Site Collection for STIs

### Other Capabilities

- Cholesterol & Lipids
- Thyroid Panel
- Testosterone
- AMH
- Gluten / Celiac
- HbA1C
- Flu Panel / COVID-19
- IDCompare


FOR MORE INFO CONTACT:

Brad Thorson, Public Health Partner


[BThorson@MolecularTestingLabs.com](mailto:BThorson@MolecularTestingLabs.com)

# STI Home Self-Monitoring Services


## ■ PlushCare



## Nurx




## ■ MyLab Box



# Telemedicine and Home Testing are not a panacea

- Digital divide: Some don't have smart phones or computers, or are challenged navigating zoom and apps
- Internet connectivity may be limited by location or plan.
- Videoconferencing about sexual health may be limited if client is not “out,” is forced into constrained environment because of pandemic (e.g. homebound students)
- Home delivery of kits may not be feasible because of privacy needs (one solution: non-clinic sites for quick screening, e.g. pharmacies, CBOs)
- Costs of all components of care may not be fully covered.



# Reimbursement for Remote Sexual Health Care



- “Can of worms”
- STI screening costs from one service ranged from \$189-369, depending on mix of tests, N mucosal sites sampled
- Tests may be provider-ordered, which will influence billing
- No single payor; states often have different regulations
- Blue Cross/Blue Shield has 35 state coverage and tends to support remote specimen collection
- Medicaid, national in theory, but states usually contract out
- NASTAD has a work group looking at billing and reimbursement for remote STI management




TAKEMEHOME – A NEW FREE HIV HOME TESTING PROGRAM

- Partnership between Building Healthy On Line Communities, Emory and NASTAD
- Advertising on several MSM social media sites
- Local health dept. uses grants to purchase kits which are order through the site
- Since March, 2020, have sent out more than 1500 HIV tests, started mailing bacterial STI self-collection kits in Sept.
- Working in more than a dozen states

[www.bhocpartners.org/home-testing/](http://www.bhocpartners.org/home-testing/)

# Need to think holistically





# Acknowledgements

**Co-Authors: Jack Turban,  
Alex Keuroghlian  
Fenway Health: Douglas Krakower  
Julian Dormitzer, Ken Levine, Chris Grasso**

**Aaron Siegler: Emory  
Wash U: Rupa Patel  
Oregon Dept of Health: Tim Menza**

**PrEP resources – National LGBTQIA+ Health Education  
Center: <https://www.lgbtqiahealtheducation.org/?s=PrEP>**



# Clinical Practice: Pre-Exposure Prophylaxis for HIV with Tele-Medicine

**Taimur H Khan MD**

Internal Medicine & Infectious Diseases  
At Fenway Health / The Fenway Institute





# Disclosures


- Sub-PI for DISCOVER [Gilead GS-US-412-2055]
- Sub-PI for PrEP@Home Study

# Agenda

- PrEP Visits trends at Fenway Health, Boston MA
- Tele-Medicine PrEP Visit Components
- Billing For Tele-Medicine PrEP Visits
- Case-Based Examples



# Trends at Fenway Health



NATIONAL LGBTQIA+ HEALTH  
EDUCATION CENTER

A PROGRAM OF THE FENWAY INSTITUTE



NATIONAL ASSOCIATION OF  
Community Health Centers

# PrEP TELEHEALTH Visits

- **Frequency**
- Hx / Symptoms/Side Effects
- Lab Testing
- Counseling
- Follow-up

**q3 months**

However, I will continue to  
refill PrEP if requested  
without appointment for 1-2  
months

# PrEP TELEHEALTH Visits

- Frequency
- Hx / Symptoms/Side Effects
- Lab Testing
- Counseling
- Follow-up

1. Assessing adherence & risk
2. Performing a thorough clinical review of systems (ROS)
3. Assessing mental health
4. Assessing substance/alcohol use
5. Assessing SDOH



# PrEP TELEHEALTH Visits

- Frequency
- Hx / Symptoms/Side Effects
- **Lab Testing**
- Counseling
- Follow-up

1. Symptomatic v Asymptomatic
2. Serum +/- Specimens
3. Location of testing
  - At Fenway (On Site)
  - At Quest Labs (In State)
  - Can it be compounded with additional services?



# PrEP TELEHEALTH Visits

- Frequency
- Hx / Symptoms/Side Effects
- Lab Testing
- **Counseling**
- Follow-up

1. Medication Adherence
  - Starting/Stopping PrEP
  - On Demand PrEP
  - Need for Non-occupational post exposure prophylaxis (NPEP)
2. Sexual Health
3. Drug/Alcohol Abuse
4. Mental Health



# PrEP TELEHEALTH Visits

- Frequency
- Hx / Symptoms/Side Effects
- Lab Testing
- Counseling
- **Follow-up**

1. Location of testing
2. Offer Mailing Refills
3. Is a nursing visit indicated?
  - Vaccine Visit: COVID-19 /HPV/HAV/HBV
  - Need for vitals
  - Need for empiric treatment





# PrEP Visit Billing

**Table 2 – CPT E/M Office Revisions  
Level of Medical Decision Making (MDM)**

**Revisions effective January 1, 2021:**

*Note: this content will not be included in the CPT 2020 code set release*



Code	Level of MDM (Based on 2 out of 3 Elements of MDM)	Number and Complexity of Problems Addressed	Elements of Medical Decision Making Amount and/or Complexity of Data to be Reviewed and Analyzed <small>*Each unique test, order, or document contributes to the combination of 2 or combination of 3 in Category 1 below.</small>	Risk of Complications and/or Morbidity or Mortality of Patient Management
99211	N/A	N/A	N/A	N/A
99202 99212	Straightforward	Minimal • 1 self-limited or minor problem	Minimal or none	Minimal risk of morbidity from additional diagnostic testing or treatment
99203 99213	Low	• 2 or more self-limited or minor problems; or • 1 stable chronic illness; or • 1 acute, uncomplicated illness or injury	Limited (Must meet the requirements of at least 1 of the 2 categories) Category 1: Tests and documents • Any combination of 2 from the following: • Review of prior external note(s) from each unique source*; • Review of the result(s) of each unique test*; • Ordering of each unique test* or Category 2: Assessment requiring an independent historian(s) (For the categories of independent interpretation of tests and discussion of management or test interpretation, see moderate or high)	Low risk of morbidity from additional diagnostic testing or treatment
99204 99214	Moderate	Moderate • 1 or more chronic illnesses with exacerbation, progression, or side effects of treatment; or • 2 or more stable chronic illnesses; or • 1 undiagnosed new problem with uncertain prognosis; or • 1 acute illness with systemic symptoms; or • 1 acute complicated injury	Moderate (Must meet the requirements of at least 2 out of 3 categories) Category 1: Tests, documents, or independent historian(s) • Any combination of 3 from the following: • Review of prior external note(s) from each unique source*; • Review of the result(s) of each unique test*; • Ordering of each unique test*; • Assessment requiring an independent historian(s) or Category 2: Independent interpretation of tests • Independent interpretation of a test performed by another physician/other qualified health care professional (not separately reported); or Category 3: Discussion of management or test interpretation • Discussion of management or test interpretation with external physician/other qualified health care professional/appropriate source (not separately reported)	Moderate risk of morbidity from additional diagnostic testing or treatment  Examples only: • Prescription drug management • Decision regarding minor surgery with identified patient or procedure risk factors • Decision regarding elective major surgery without identified patient or procedure risk factors • Diagnosis or treatment significantly limited by social determinants of health
99205 99215	High	High • 1 or more chronic illnesses with severe exacerbation, progression, or side effects of treatment; or • 1 acute or chronic illness or injury that poses a threat to life or bodily function	Extensive (Must meet the requirements of at least 2 out of 3 categories) Category 1: Tests, documents, or independent historian(s) • Any combination of 3 from the following: • Review of prior external note(s) from each unique source*; • Review of the result(s) of each unique test*; • Ordering of each unique test*; • Assessment requiring an independent historian(s) or Category 2: Independent interpretation of tests • Independent interpretation of a test performed by another physician/other qualified health care professional (not separately reported); or Category 3: Discussion of management or test interpretation • Discussion of management or test interpretation with external physician/other qualified health care professional/appropriate source (not separately reported)	High risk of morbidity from additional diagnostic testing or treatment  Examples only: • Drug therapy requiring intensive monitoring for toxicity • Decision regarding elective major surgery with identified patient or procedure risk factors • Decision regarding emergency major surgery • Decision regarding hospitalization • Decision not to resuscitate or to de-escalate care because of poor prognosis

<https://www.ama-assn.org/system/files/2019-06/cpt-office-prolonged-svs-code-changes.pdf>

CPT is a registered trademark of the American Medical Association. Copyright 2019 American Medical Association. All rights reserved.

# PrEP Visit BILLING

## Lvl 3 vs Lvl 4

Billing for complexity

Billing for time (AV vs Phone)

99203 99213	Low	<b>Low</b> <ul style="list-style-type: none"> <li>• 2 or more self-limited or minor problems;</li> <li>or</li> <li>• 1 stable chronic illness;</li> <li>or</li> <li>• 1 acute, uncomplicated illness or injury</li> </ul>	<b>Limited</b> <i>(Must meet the requirements of at least 1 of the 2 categories)</i> <p><b>Category 1: Tests and documents</b></p> <ul style="list-style-type: none"> <li>• Any combination of 2 from the following: <ul style="list-style-type: none"> <li>• Review of prior external note(s) from each unique source*;</li> <li>• review of the result(s) of each unique test*;</li> <li>• ordering of each unique test*</li> </ul> </li> </ul> <p>or</p> <p><b>Category 2: Assessment requiring an independent historian(s)</b>  <i>(For the categories of independent interpretation of tests and discussion of management or test interpretation, see moderate or high)</i></p>	Low risk of morbidity from additional diagnostic testing or treatment
----------------	-----	---	---	---

99204 99214	Moderate	<b>Moderate</b> <ul style="list-style-type: none"> <li>• 1 or more chronic illnesses with exacerbation, progression, or side effects of treatment;</li> <li>or</li> <li>• 2 or more stable chronic illnesses;</li> <li>or</li> <li>• 1 undiagnosed new problem with uncertain prognosis;</li> <li>or</li> <li>• 1 acute illness with systemic symptoms;</li> <li>or</li> <li>• 1 acute complicated injury</li> </ul>	<b>Moderate</b> <i>(Must meet the requirements of at least 1 out of 3 categories)</i> <p><b>Category 1: Tests, documents, or independent historian(s)</b></p> <ul style="list-style-type: none"> <li>• Any combination of 3 from the following: <ul style="list-style-type: none"> <li>• Review of prior external note(s) from each unique source*;</li> <li>• Review of the result(s) of each unique test*;</li> <li>• Ordering of each unique test*;</li> <li>• Assessment requiring an independent historian(s)</li> </ul> </li> </ul> <p>or</p> <p><b>Category 2: Independent interpretation of tests</b></p> <ul style="list-style-type: none"> <li>• Independent interpretation of a test performed by another physician/other qualified health care professional (not separately reported);</li> </ul> <p>or</p> <p><b>Category 3: Discussion of management or test interpretation</b></p> <ul style="list-style-type: none"> <li>• Discussion of management or test interpretation with external physician/other qualified health care professional, appropriate source (not separately reported)</li> </ul>	Moderate risk of morbidity from additional diagnostic testing or treatment  <i>Examples only:</i> <ul style="list-style-type: none"> <li>• Prescription drug management</li> <li>• Decision regarding minor surgery with identified patient or procedure risk factors</li> <li>• Decision regarding elective major surgery without identified patient or procedure risk factors</li> <li>• Diagnosis or treatment significantly limited by social determinants of health</li> </ul>
----------------	----------	--	---	---



# PrEP Visit

## Billing for Time

**99213** Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and **low level of medical decision making (Lvl 2 +)**.

When using time for code selection, **20-29 minutes of total time** is spent on the date of the encounter.

**99214** Office or other outpatient visit for the evaluation and management of an established patient, which requires a medically appropriate history and/or examination and **moderate level of medical decision making (Lvl 3 +)**.

When using time for code selection, **30-39 minutes of total time** is spent on the date of the encounter.

*When billing for time, especially with phone visits, it has to be clearly documented, with exact time spent.*



# PrEP Case #1

35yo cisgender MSM presents for PrEP follow-up. He states that he has not been sexually active with any new partners during COVID; his primary partner is HIV + (undetectable for over 5 years). Previously he would have 1-2 new sexual partners every 3 months. He is a PhD candidate, drinks one glass of wine twice a week, denies any other drug use, is not on any other medications.

1. If he is on the fence about continuing PrEP, what would you tell him about his risk?
2. If he would like to stop taking PrEP and possibly restart later, how would you counsel him to restart?
3. If he is thinking of stopping, would you have him get testing done now, if he has not had any new partners since pre-COVID?

# PrEP Case #2

25yo transgender female presents for a PrEP follow-up via Tele-Medicine. She states that she ran out of her FTC/TDF a month ago and was not sexually active over last three months due to lockdown. However, she admits to having had transactional sex last night with an HIV+ person (unknown detectability). She would like to restart PrEP immediately as she plans on seeing that same person next weekend. She is also due for her HPV #3 vaccine.

1. Do you prescribe her FTC/TDF now or wait for the results of her testing?
2. How would you streamline her follow-up?
3. Any other counselling required at this time?



# PrEP Case #3

70yo cisgender male with history of Stage 2 CKD presents for PrEP follow-up via Tele-Medicine. He states that he has not missed any of his FTC/TAF. He is currently asymptomatic for acute STIs. Reports 15 new sexual partners since his last appointment 3 months ago. He reports increase anxiety. He is visibly more irritable during the visit. His electronic survey results reveal an elevated GAD-7 score and some “risky substance use”. He also reports that one of his partners recently told him he was tested and treated for syphilis (after their encounter).

1. How to you manage this tele-health visit? What takes priority?
2. How do you manage his follow-up?



# Thank you

**PrEP resources – National LGBTQIA+ Health Education Center:** <https://www.lgbtqiahealtheducation.org/?s=PrEP>





# NATIONAL LGBTQIA+ HEALTH EDUCATION CENTER

A PROGRAM OF THE FENWAY INSTITUTE

The National LGBTQIA+ Health Education Center provides educational programs, resources, and consultation to health care organizations with the goal of optimizing quality, cost-effective health care for lesbian, gay, bisexual, transgender, queer, intersex, asexual, and all sexual and gender minority (LGBTQIA+) people.

The Education Center is part of The Fenway Institute, the research, training, and health policy division of Fenway Health, a Federally Qualified Health Center, and one of the world's largest LGBTQIA+ focused health centers.

.....

 617.927.6354

 [education@fenwayhealth.org](mailto:education@fenwayhealth.org)

 [www.lgbtqiahealtheducation.org](http://www.lgbtqiahealtheducation.org)

 [www.acponline.org/fenway](http://www.acponline.org/fenway)

